M&A

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Sarepta Therapeutics falls sharply after suspending shipments of Elevidys for infusions in non-ambulatory patients because of the death of a second patient from acute liver failure.

With President Donald Trump’s blessing, Nippon Steel can complete its “investment” in U.S. Steel. It’s really an acquisition.

The deal is worth an initial $561 million, with potential for $234 million in add-ons.

Crane’s deal for a Baker Hughes sensing business bulks up its nuclear exposure. That’s good news, according to Deutsche Bank analyst Scott Deuschle.

IonQ says the deal will accelerate its mission to build fault-tolerant machines by 2030.

The company is making a big push to get its central processing unit chips used in the data-center market.

The insurance and annuities provider has been making a series of acquisitions to establish an advisory platform catering to distinct client segments.

Kevin Casey, who leads M&A for Pathstone, sees acquisition candidates in law practices and tax boutiques, as well as traditional RIAs.

The addition of Buffington Mohr McNeal expands EP’s footprint in the West.

Brazilian pulp and paper maker Suzano will hold a majority stake in a new venture.

The $19 billion deal adds to a potential comeback in M&A activity among industrials companies.

In its fourth deal of the year, Mariner adds a New York practice that provides complex services to wealthy clients, including those who made their money in professional sports.

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people familiar with the matter.

The purchase of Full Sail Capital is Mercer’s sixth deal of the year, continuing an aggressive acquisition campaign.

The dollar’s worst start to a year on record, Bristol Myers plans to develop new cancer drug, Apple’s WWDC is coming, and more news to start your day.

Shares of steel companies soar after President Donald Trump says he will raise tariffs on imported steel to 50% from 25%.

The deal announced Monday is Sanofi's third of the year so far.

The retailer has strung together a remarkable record of sales growth that makes the stock look like a bargain.

While the deal to buy cosmetics brand Rhode is a positive, it remains to be seen how the company will navigate macro uncertainty, analysts say.

The company is buying Informatica, a provider of data-management and integration services, to support Agentforce, its AI play.

More than half the public shareholders in Endeavor Group Holdings are poised to challenge Silver Lake in Delaware Chancery Court.

Mergers and acquisitions were dead earlier this year before turning on a dime when President Donald Trump paused tariffs.

Stock in the legendary manufacturer has almost reached the price Nippon Steel has offered. Investors should take profits.

Apple rises after tumbling Friday when President Donald Trump threatened a 25% tariff on iPhones sold in the U.S. that are made overseas, while Tesla trades higher even as the electric-vehicle maker’s sales in Europe decline for a fourth straight month.